Zanubrutinib, lenalidomide and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as initial treatment in non–germinal center B-cell diffuse large B-cell lymphoma: a multi-center phase 2 study by Jiangsu Cooperative Lymphoma Group (JCLG)
Saved in:
| Title: | Zanubrutinib, lenalidomide and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as initial treatment in non–germinal center B-cell diffuse large B-cell lymphoma: a multi-center phase 2 study by Jiangsu Cooperative Lymphoma Group (JCLG) |
|---|---|
| Authors: | Xia, Yi1,2,3 (AUTHOR) cynthia0311@163.com, Miao, Yi1,2,3 (AUTHOR), Qian, Siqi1,2,3 (AUTHOR), Zhang, Run1,2,3 (AUTHOR), Qin, Shuchao1,2,3 (AUTHOR), Xie, Xiaoyan4 (AUTHOR), Li, Bingzong5 (AUTHOR), Sha, Yeqin1,2,3 (AUTHOR), Tang, Hanning1,2,3 (AUTHOR), Jin, Hui1,2,3 (AUTHOR), Cao, Lei1,2,3 (AUTHOR), Xu, Wei1,2,3 (AUTHOR), Fan, Lei1,2,3 (AUTHOR), Li, Jianyong1,2,3 (AUTHOR) lijianyonglm@163.com, Shi, Wenyu6,7 (AUTHOR) shiwenyu@hotmail.com, Zhu, Huayuan1,2,3 (AUTHOR) huayuan.zhu@hotmail.com |
| Source: | BMC Medicine. 10/24/2025, Vol. 23 Issue 1, p1-13. 13p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
